AEterna Zentaris Breakout on FDA Catalysts

Breaking News and Insider Scoops April 21, 2011 AEterna Zentaris Placed On Breakout Alert Ahead of FDA Catalysts (NASDAQ:AEZS) AEterna Zentaris has three critical FDA catalysts coming up in the 2nd half of the year which could propel it to new highs: 1) Perifosine (KRX-0401) Pivotal Phase 3 study completion and top-line results, an inhibitor anti-cancer agent for relapsed / refractory multiple myeloma. 2) SOLOREL, treatment of maci-morelin (AEZS-130), announced SPA agreement and expects results during 1st half 2011 to support NDA filing by end of year. 3) AEZS-108, a LHRH agonist linked doxorubicin conjugate, for endometrial cancer, expects to begin phase 3 pivotal study in mid 2011. Technical Analysis: Full chart: http://chart.ly/uploads/large_8wgyu72.png?1303395241 We will have a report coming out this weekend on potential target market, price target, financial conditions and more. Latest Updates $AEZS looks to breakout to new 52-week highs $AVNR partnership may be close, expect stellar earnings report © Copyright 2010 MiV Investments Inc., TheMarketFinancial.com